Compound details
Hesperidin
| Compound ID | CDAMM00551 |
|---|---|
| Common name | Hesperidin | IUPAC name | 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one |
| Molecular formula | C28H34O15 |
| Retention time | 12.75 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 611.198 | Theoretical mz | 611.197 |
| Error | 1.35 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 7.2543 |
| Inchi key | QUQPHWDTPGMPEX-SHXQGXTJNA-N |
|---|---|
| Smiles | O=C1C2=C(O)C=C(OC3OC(COC4OC(C)C(O)C(O)C4O)C(O)C(O)C3O)C=C2OC(C5=CC=C(OC)C(O)=C5)C1 |
| Superclass | Phenylpropanoids and polyketides |
| Class | Flavonoids |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P43166 | CA7 | Carbonic anhydrase VII | T37541 | SEA |
| P11926 | ODC1 | Ornithine decarboxylase | T60366 | SEA |
| P11511 | CYP19A1 | Cytochrome P450 19A1 | T13260 | SwissTargetPrediction and SEA |
| P20151 | KLK2 | Kallikrein 2 | T01908 | SEA |
| P60568 | IL2 | Interleukin-2 | T61698 | SEA |
| Q9NUW8 | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | T33492 | SEA |
| P04746 | AMY2A | Pancreatic alpha-amylase | T86918 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| Q9GZQ4 | NMUR2 | Neuromedin-U receptor 2 | T04210 | SEA |
| P47989 | XDH | Xanthine dehydrogenase | T40954 | SEA |
| Q16678 | CYP1B1 | Cytochrome P450 1B1 | T92521 | SEA |
| P16152 | CBR1 | Carbonyl reductase [NADPH] 1 | T70518 | SEA |
| Q9NZ08 | ERAP1 | Endoplasmic reticulum aminopeptidase 1 | T72849 | SEA |
| P30837 | ALDH1B1 | Acetaldehyde dehydrogenase | T99641 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T60366 | DI0020 | African trypanosomiasis | [ICD-11: 1F51] | P11926 | ODC1 |
| T13260 | DI0062 | Breast cancer | [ICD-11: 2C60-2C6Y] | P11511 | CYP19A1 |
| T13260 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P11511 | CYP19A1 |
| T01908 | DI0213 | Innate/adaptive immunodeficiency | [ICD-11: 4A00] | P20151 | KLK2 |
| T61698 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P60568 | IL2 |
| T61698 | DI0361 | Renal cell carcinoma | [ICD-11: 2C90] | P60568 | IL2 |
| T86918 | DI0110 | Cystic fibrosis | [ICD-11: CA25] | P04746 | AMY2A |
| T86918 | DI0328 | Pancreatic malfunction | [ICD-11: DC30-DC3Z] | P04746 | AMY2A |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T40954 | DI0206 | Inborn purine/pyrimidine/nucleotide metabolism error | [ICD-11: 5C55] | P47989 | XDH |
| T40954 | DI0266 | Mineral deficiency | [ICD-11: 5B5K] | P47989 | XDH |
| T70518 | DI0037 | Asthma | [ICD-11: CA23] | P16152 | CBR1 |
| T99641 | DI0396 | Substance abuse | [ICD-11: 6C40] | P30837 | ALDH1B1 |